Home  »  News   »  ACRS’s Stock Market Adventure: -49.91% YTD G...

ACRS’s Stock Market Adventure: -49.91% YTD Growth Amidst Volatility

Investors’ outlook regarding the stock price performance over the year has been split, with some feeling optimistic and others feeling pessimistic, as it’s been a mixed bag. The metric has seen a significant loss of -49.91% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -1.26%. Over the past 30 days, the price of ACRS has fallen by 1.53%. And in the last five days, it has surged by 4.22%.

The stock of Aclaris Therapeutics Inc. (ACRS) is currently priced at $7.89. In the last session, the stock climbed significantly, topping out at $7.78 after opening at $7.64. The day’s lowest price was $7.55 before the stock closed at $7.58.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Aclaris Therapeutics Inc. saw a rather unpredictable run in, in terms of market performance. The company’s stock reached its highest point at $18.96 on 11/16/22, while the lowest price for the same duration was marked at $5.77 on 03/06/23.

52-week price history of ACRS Stock

Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. Aclaris Therapeutics Inc.’s current trading price is -58.39% away from its 52-week high, while its distance from the 52-week low is 36.73%. The stock’s price range during this time has been between $5.77 and $18.96. The trading volume for the Healthcare sector company’s shares reached about 0.8 million for the day, which was higher than the average daily volume of 0.69 million over the last three months.

Market Capitalization vs. Financial Performance: A Comparative Study

Aclaris Therapeutics Inc. (ACRS) has experienced a quarterly decline of -17.22% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 542.70M and boasts a workforce of 105 employees.

Combining Moving Average and Trading Volume Data for Better Market Insight

Based on Barchart.com data, the company’s moving average over the 100-day period was 8.97, with a change in price of -1.25. Similarly, Aclaris Therapeutics Inc. recorded 659,341 in trading volume during the last 100 days, posting a change of -13.66%.

ACRS’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look

The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for ACRS stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.

ACRS Stock Stochastic Average

Today, Aclaris Therapeutics Inc.’s raw stochastic average for the past 50 days stands at 30.01%, indicating a decline from the raw stochastic average of the last 20 days, which was 79.80%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 69.50% and 69.12% respectively.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts